Lourd Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Lourd Capital’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$342K	Buy	1,863 +43	+2%	+$7.52K	0.03%	85
2019 Q1	$335K	Sell	1,820 -1,112	-38%	-$205K	0.03%	84
2018 Q4	$486K	Buy	2,932 +10	+0.3%	+$1.73K	0.04%	121
2018 Q3	$563K	Buy	+2,922	New	+$520K	0.04%	115
2018 Q1	–	Sell	-1,552	Closed	-$233K	–	329
2017 Q4	$233K	Buy	+1,552	New	+$230K	0.02%	298

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Lourd Capital's VRTX Position: Q2 2019 in Review

Lourd Capital increased its Vertex Pharmaceuticals (VRTX) stake by 2.4% in Q2 2019, buying an estimated $7.52K and bringing the position to 1,863 shares worth $342K. The position accounts for 0.03% of the portfolio, ranked #85.

Lourd Capital first reported a position in VRTX in Q4 2017 and has held it in 5 quarters since. The position peaked at $563K in Q3 2018. 716 funds tracked by Wall St. Rank hold VRTX as of Q2 2019.

Lourd Capital held 1,863 shares of Vertex Pharmaceuticals worth $342K as of Q2 2019.
Lourd Capital bought 43 Vertex Pharmaceuticals shares in Q2 2019, an estimated $7.52K.
Vertex Pharmaceuticals made up 0.03% of Lourd Capital's portfolio in Q2 2019, its #85 holding.
Lourd Capital first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 5 quarters since.
Lourd Capital's Vertex Pharmaceuticals position peaked at $563K in Q3 2018.
716 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2019.

Based on Lourd Capital's 13F filing for Q2 2019, filed 11 Jul 2019.